JP4643899B2 - イブプロフェン含有錠剤およびその製造方法 - Google Patents
イブプロフェン含有錠剤およびその製造方法 Download PDFInfo
- Publication number
- JP4643899B2 JP4643899B2 JP2003359602A JP2003359602A JP4643899B2 JP 4643899 B2 JP4643899 B2 JP 4643899B2 JP 2003359602 A JP2003359602 A JP 2003359602A JP 2003359602 A JP2003359602 A JP 2003359602A JP 4643899 B2 JP4643899 B2 JP 4643899B2
- Authority
- JP
- Japan
- Prior art keywords
- ibuprofen
- powder
- bulk powder
- tableting
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title claims description 83
- 229960001680 ibuprofen Drugs 0.000 title claims description 83
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 239000000843 powder Substances 0.000 claims description 61
- 239000002245 particle Substances 0.000 claims description 31
- 239000008187 granular material Substances 0.000 claims description 29
- 238000000748 compression moulding Methods 0.000 claims description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 229920002678 cellulose Polymers 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 239000000454 talc Substances 0.000 description 7
- 229910052623 talc Inorganic materials 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- 235000012239 silicon dioxide Nutrition 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229960001948 caffeine Drugs 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 3
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 3
- BFSMWENDZZIWPW-UHFFFAOYSA-N Isopropamide iodide Chemical compound [I-].C=1C=CC=CC=1C(C(N)=O)(CC[N+](C)(C(C)C)C(C)C)C1=CC=CC=C1 BFSMWENDZZIWPW-UHFFFAOYSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 3
- 229960000920 dihydrocodeine Drugs 0.000 description 3
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 3
- 229940073563 dl- methylephedrine hydrochloride Drugs 0.000 description 3
- 229960001543 isopropamide iodide Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 3
- 229960004708 noscapine Drugs 0.000 description 3
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- -1 hydroxypropyl Chemical group 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
Description
リン酸ジヒドロコデイン 24g、dl−塩酸メチルエフェドリン 60g、ヨウ化イソプロパミド 6g、ノスカピン 48g、マレイン酸クロルフェニラミン 7.5g、アスコルビン酸 300g、硝酸チアミン 24g、無水カフェイン 75gに、結晶セルロース、軽質無水ケイ酸、乳糖、ヒドロキシプロピルセルロースなどの賦形剤1408.5gを加えた粉体混合物に精製水を加えて湿式造粒した後、乾燥し、顆粒を作製した。この顆粒をコーミル(パウレック社製)にて整粒し1953gの顆粒を得た(A)。
イブプロフェン原末を140メッシュ(目開き106μm)と22メッシュ(目開き710μm)の篩を用いて整粒し、粒子径が106〜710μmのイブプロフェン原末450gを得た(C)。
無水カフェイン 240gに、結晶セルロース、低置換度ヒドロキシプロピルセルロース、乳糖、ヒドロキシプロピルセルロースなどの賦形剤546gを加えた粉体混合物に精製水を加えて湿式造粒した後、乾燥し、顆粒を作製した。この顆粒をコーミル(パウレック社製)にて整粒し、786gの顆粒を得た(D)。
リン酸ジヒドロコデイン 24g、dl−塩酸メチルエフェドリン 60g、ヨウ化イソプロパミド 6g、ノスカピン 48g、マレイン酸クロルフェニラミン 7.5g、アスコルビン酸 300g、硝酸チアミン 24g、無水カフェイン 75gに、結晶セルロース、軽質無水ケイ酸、乳糖、ヒドロキシプロピルセルロースなどの賦形剤1208.5gを加えて粉体混合物を得た。これに精製水を加えて湿式造粒した後、乾燥し、顆粒を作製した。この顆粒をコーミル(パウレック製)で整粒した(F)。
篩による整粒を行わないイブプロフェン原末450gを用意する(H)。
実施例1で得た整粒した顆粒(A)1953gとイブプロフェン原末(H)450gを混合した後、タルク 15gおよびステアリン酸マグネシウム 12gを加えて更に混合した。この混合物をロータリー打錠機にて打錠し、270mg/tb.の素錠を製した。
イブプロフェン原末 450g、リン酸ジヒドロコデイン 24g、dl−塩酸メチルエフェドリン 60g、ヨウ化イソプロパミド 6g、ノスカピン 48g、マレイン酸クロルフェニラミン 7.5g、アスコルビン酸 300g、硝酸チアミン 24g、無水カフェイン 75gに、結晶セルロース、軽質無水ケイ酸、乳糖、ヒドロキシプロピルセルロースなどの賦形剤1408.5gを加えた粉体混合物に精製水を加えて湿式造粒した後、乾燥し、顆粒を作製した。この顆粒をコーミル(パウレック製)で整粒した(I)。
実施例1〜4、比較例1および2の素錠を製造する際のスティッキングを調べた。素錠製造のための打錠は、いずれもロータリー打錠機に臼杵を2組セットし、ターンテーブルの回転数30rpmで行い、90分間打錠した後の杵へのスティッキングを観察した。この結果を表1に示す。
Claims (8)
- 70質量%以上の粒子の粒子径が、75μm〜1000μmであるイブプロフェン原末を打錠末として圧縮成型することにより得られたイブプロフェン含有錠剤。
- 70質量%以上の粒子の粒子径が、106μm〜710μmであるイブプロフェン原末を打錠末として圧縮成型することにより得られたイブプロフェン含有錠剤。
- 70質量%以上の粒子の粒子径が、150μm〜500μmであるイブプロフェン原末を打錠末として圧縮成型することにより得られたイブプロフェン含有錠剤。
- イブプロフェンの含量が10〜50質量%である請求項第1項ないし第3項記載のイブプロフェン含有錠剤。
- イブプロフェン原末およびイブプロフェン含有顆粒を混合して使用した請求項第1項ないし第4項の何れかの項記載のイブプロフェン含有錠剤。
- イブプロフェン原末を、その70質量%以上の粒子の粒子径が、75μm〜1000μmとなるように調整した後、これを打錠末として圧縮成型することを特徴とするイブプロフェン含有錠剤の製造方法。
- イブプロフェン原末を、その70質量%以上の粒子の粒子径が、106μm〜710μmとなるように調整した後、これを打錠末として圧縮成型することを特徴とするイブプロフェン含有錠剤の製造方法。
- イブプロフェン原末を、その70質量%以上の粒子の粒子径が、150μm〜500μmとなるように調整した後、これを打錠末として圧縮成型することを特徴とするイブプロフェン含有錠剤の製造方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003359602A JP4643899B2 (ja) | 2003-10-20 | 2003-10-20 | イブプロフェン含有錠剤およびその製造方法 |
TW093128065A TWI362948B (en) | 2003-10-20 | 2004-09-16 | Ibuprofen tablet and its preparation method |
KR1020040076408A KR20050037942A (ko) | 2003-10-20 | 2004-09-23 | 이부프로펜 함유 정제 및 그의 제조방법 |
CN200610055013.4A CN1853615B (zh) | 2003-10-20 | 2004-10-09 | 含有布洛芬的药片及其制造方法 |
CNA2004100856102A CN1636558A (zh) | 2003-10-20 | 2004-10-09 | 含有布洛芬的药片及其制造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003359602A JP4643899B2 (ja) | 2003-10-20 | 2003-10-20 | イブプロフェン含有錠剤およびその製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005120058A JP2005120058A (ja) | 2005-05-12 |
JP4643899B2 true JP4643899B2 (ja) | 2011-03-02 |
Family
ID=34615777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003359602A Expired - Lifetime JP4643899B2 (ja) | 2003-10-20 | 2003-10-20 | イブプロフェン含有錠剤およびその製造方法 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP4643899B2 (ja) |
KR (1) | KR20050037942A (ja) |
CN (2) | CN1853615B (ja) |
TW (1) | TWI362948B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4845087B2 (ja) * | 2005-05-27 | 2011-12-28 | エスエス製薬株式会社 | 経口投与用製剤 |
JP4864369B2 (ja) * | 2005-07-21 | 2012-02-01 | 第一三共ヘルスケア株式会社 | チアミン類の安定化方法 |
JP5974469B2 (ja) * | 2010-12-24 | 2016-08-23 | ライオン株式会社 | 錠剤の製造方法 |
CN114982778A (zh) * | 2022-06-20 | 2022-09-02 | 戴景文 | 一种长效缓释消毒水体的复配次氯酸钙饼剂的制备工艺及缓释性能测试方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000500477A (ja) * | 1995-11-22 | 2000-01-18 | レコルダチ エッセ.ア.ケミカル アンド ファーマシューティカル カンパニー | 即時放出型の薬学的組成物 |
JP2001518491A (ja) * | 1997-10-03 | 2001-10-16 | エフエムシー・コーポレイション | 味覚マスクされた薬学的組成物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1226549B (it) * | 1988-07-12 | 1991-01-24 | Resa Farma | Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose. |
-
2003
- 2003-10-20 JP JP2003359602A patent/JP4643899B2/ja not_active Expired - Lifetime
-
2004
- 2004-09-16 TW TW093128065A patent/TWI362948B/zh not_active IP Right Cessation
- 2004-09-23 KR KR1020040076408A patent/KR20050037942A/ko not_active Application Discontinuation
- 2004-10-09 CN CN200610055013.4A patent/CN1853615B/zh not_active Expired - Fee Related
- 2004-10-09 CN CNA2004100856102A patent/CN1636558A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000500477A (ja) * | 1995-11-22 | 2000-01-18 | レコルダチ エッセ.ア.ケミカル アンド ファーマシューティカル カンパニー | 即時放出型の薬学的組成物 |
JP2001518491A (ja) * | 1997-10-03 | 2001-10-16 | エフエムシー・コーポレイション | 味覚マスクされた薬学的組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP2005120058A (ja) | 2005-05-12 |
TW200514578A (en) | 2005-05-01 |
KR20050037942A (ko) | 2005-04-25 |
CN1636558A (zh) | 2005-07-13 |
CN1853615A (zh) | 2006-11-01 |
TWI362948B (en) | 2012-05-01 |
CN1853615B (zh) | 2014-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1027037B1 (en) | Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient | |
WO2006123243A2 (en) | Pharmaceutical dosage forms comprising escitalopram in form of granules | |
WO2017217491A1 (ja) | 口腔内崩壊錠 | |
JP4643899B2 (ja) | イブプロフェン含有錠剤およびその製造方法 | |
EP3256106B1 (en) | Method of preparing an extruded composition | |
KR20160002177A (ko) | 오셀타미비어 유리염기를 포함하는 약학 조성물 | |
GB2444904A (en) | A process for the preparation of an orally administered unit dose tablet | |
US20030211150A1 (en) | Immediate release tablet containing naproxen sodium | |
JP6297930B2 (ja) | イブプロフェン含有錠剤およびその製造方法 | |
EP2671569B1 (en) | Stable pharmaceutical compositions with fast onset | |
JP6887506B2 (ja) | ドネペジル又はその薬学的に許容可能な塩及びメマンチン又はその薬学的に許容可能な塩を含む認知症(dementia)及び認知機能障害の予防又は治療用薬学組成物及びその製造方法 | |
KR102373089B1 (ko) | 이부프로펜 및 아세트아미노펜을 포함하는 약제학적 조성물 및 이의 제조방법 | |
JP2004352633A (ja) | 酸化マグネシウム錠剤 | |
JP2019089758A (ja) | セレコキシブ含有錠剤における溶出性の改善方法 | |
KR20200137878A (ko) | 건식과립 조성물 및 이를 이용한 정제 및 이의 제조 방법 | |
US10188607B2 (en) | Pharmaceutical formulation of racecadotril | |
JP2020055776A (ja) | メマンチン又はその薬物学的に許容される塩を含む医薬組成物及びその製造方法 | |
JP5900702B2 (ja) | 経口投与用医薬組成物 | |
KR20190031660A (ko) | 안정성이 개선된 습식과립 정제 및 이의 제조방법 | |
JP4573542B2 (ja) | ビタミンb1誘導体組成物 | |
KR20160140567A (ko) | 오셀타미비어 유리염기를 포함하는 약학 조성물 | |
KR20240055103A (ko) | 벰페도산의 약학 조성물 | |
JP2016510787A (ja) | クリゾチニブを含む剤形 | |
WO2020249500A1 (en) | Stable tablet formulation of nifurtimox and process for producing the same | |
RU2289422C2 (ru) | Фармацевтическая композиция на основе ноопепта |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060915 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100414 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100414 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100901 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20101021 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101116 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101203 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4643899 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131210 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |